Prophylactic or therapeutic administration of Agaricus blazei Murill is effective in treatment of murine visceral leishmaniasis

Experimental Parasitology

Volumn 132, Issue 2, 2012, Pages 228-236

  Valadares, Diogo G ^a   Duarte, Mariana C ^a   Ramírez, Laura ^b   Chávez Fumagalli, Miguel A ^a   Martins, Vivian T ^a   Costa, Lourena E ^a   Lage, Paula S ^a   Ribeiro, Tatiana G ^a   Castilho, Rachel O ^a   Fernandes, Ana Paula ^a   Régis, Wiliam C B ^c,d   Soto, Manuel ^b   Tavares, Carlos A P ^a   Coelho, Eduardo A F ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c Minasfungi do Brasil Ltda   (Brazil)

^d PONTIFICAL CATHOLIC UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Agaricus Blazei Murill; BALB c mice; Chemo prophylaxis; Oral treatment; Purified fractions; Visceral leishmaniasis

Indexed keywords

AGARICUS BLAZEI EXTRACT; AMPHOTERICIN B DEOXYCHOLATE; INTERLEUKIN 10; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTILEISHMANIAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARASITE LOAD; PHYTOCHEMISTRY; PRIORITY JOURNAL; SPLEEN CELL; THIN LAYER CHROMATOGRAPHY; VISCERAL LEISHMANIASIS;

AGARICUS; ANIMALS; ANTIPROTOZOAL AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOLYSIS; INHIBITORY CONCENTRATION 50; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIVER; LYMPH NODES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN;

AGARICUS BLAZEI; ANIMALIA; LEISHMANIA DONOVANI CHAGASI; MURINAE; MUS;

EID: 84866425729     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2012.07.005     Document Type: Article

References (37)

1. Aguiar M.G., Pereira A.M.M., Fernandes A.P., Ferreira L.A.M. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis. Antimicrob. Agents Chemther. 2010, 54:4699-4704.
2. Basu R., Bhaumik S., Haldar A.K., Naskar K., De T., Dana S.K., Walden P., Roy S. Hybrid cell vaccination resolves Leishmania donovani infection by eliciting a strong CD8+ cytotoxic T-lymphocyte response with concomitant suppression of interleukin-10 (IL-10) but not IL-4 or IL-13. Infect. Immun. 2007, 75:5956-5966.
3. Berman F. Clinical status of agents being developed for Leishmaniasis. Expert Opin. Invest. Drugs 2005, 14:1337-1346.
4. Bernardshaw S., Johnson E., Hetlandy G. An extract of the mushroom Agaricus blazei Murill administered orally protects against systemic Streptococcus pneumoniae infection in mice. Scand. J. Immunol. 2005, 62:393-398.
5. Bernardshaw S., Hetland G., Ellertsen L.K., Tryggestad A.M.A., Johnson E. An extract of the medicinal mushroom Agaricus blazei Murill differentially stimulates production of pro-inflammatory cytokines in human monocytes and human vein endothelial cells in vitro. Inflammation 2006, 29:147-153.
6. Bernardshaw S., Lyberg T., Hetland G., Johnson E. Effect of an extract of the mushroom Agaricus blazei Murill on expression of adhesion molecules and production of reactive oxygen species in monocytes and granulocytes in human whole blood ex vivo. APMIS 2007, 115:719-725.
7. Brown G.D., Gordon S. Fungal beta-glucans and mammalian immunity. Immunity 2003, 19:311-315.
8. Carneiro G., Santos D.C., Oliveira M.C., Fernandes A.P., Ferreira L.S., Ramaldes G.A., Nunan E.A., Ferreira L.A. Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis. J. Liposome Res. 2010, 20:16-23.
9. Carrión J., Nieto A., Iborra S., Iniesta V., Soto M., Folgueira C., Abanades D.R., Requena J.M., Alonso C. Immunohistological features of visceral leishmaniasis in BALB/c mice. Parasite Immunol. 2006, 28:173-183.
10. Coelho E.A., Tavares C.A., Carvalho F.A., Chaves K.F., Teixeira K.N., Rodrigues R.C., Matlashewski G., Gazzinelli R.T., Fernandes A.P. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect. Immun. 2003, 71:3988-3994.
11. Croft S.L., Coombs G.H. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 2003, 19:502-508.
12. Dubois M., Gilles K.A., Hamilton J.K., Rebers P.A., Smith F. Colorimetric method for determination of sugars and related substances. Anal. Chem. 1956, 28:350-356.
13. Forland D.T., Johnson E., Tryggestad A.M., Lyberg T., Hetland G. An extract based on the medicinal mushroom Agaricus blazei stimulates monocyte-derived dendritic cells to cytokine and chemokine production in vitro. Cytokine 2010, 49:245-250.
14. Frézard F., Demicheli C. New delivery strategies for the old pentavalent antimonial drugs. Expert Opin. Drug Deliv. 2010, 7:1343-1358.
15. Garnier T., Croft S.L. Topical treatment for cutaneous leishmaniasis. Curr. Opin. Investig. Drugs 2002, 3:538-544.
16. Giudice E.L., Campbell J.D. Needle-free vaccine delivery. Adv. Drug Deliv. Rev. 2006, 58:68-89.
17. Grimaldi G., Tesh R.B. Leishmaniases of the New World: Current concepts and implications for future research. Clin. Microbiol. Rev. 1993, 6:230-250.
18. Kim Y.W., Kim K.H., Choi H.J., Lee D.S. Anti-diabetic activity of beta-glucans and their enzymatically hydrolyzed oligosaccharides from Agaricus blazei. Biotechnol. Lett. 2005, 27:483-487.
19. Kim C.F., Jiang J.J., Leung K.N., Fung K.P., Lau C.B. Inhibitory effects of Agaricus blazei Murill extracts on human myeloid leukemia cells. J. Ethnopharmacol. 2009, 122:320-326.
20. Kolodziej H., Kiderlen A.F. Antileishmanial activity and immune modulatory effects of tannins and related compounds on Leishmania parasitised RAW 264.7cells. Phytochemistry 2005, 66:2056-2071.
21. Maia C., Campino L. Methods for diagnosis of canine Leishmaniasis and immune response to infection. Vet. Parasitol. 2008, 158:274-287.
22. Minodier P., Parola P. Cutaneous leishmaniasis treatment. Travel Med. Infect. Dis. 2007, 5:150-158.
23. Mondal S., Bhattacharya P., Rahaman M., Ali N., Goswami R.P. A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy. PLoS Negl. Trop. Dis. 2010, 27:e764.
24. Nwaka S., Hudson A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 2006, 5:941-955.
25. Oliveira L.F., Schubach A.O., Martins M.M., Passos S.L., Oliveira R.V., Marzochi M.C., Andrade C.A. Systematic review of the adverse effects of cutaneous Leishmaniasis treatment in the New World. Acta Trop. 2011, 118:87-96.
26. Oliveira D.M., Costa M.A.F., Chavez-Fumagalli M.A., Valadares D.G., Duarte M.C., Costa L.E., Martins V.T., Gomes R., Melo M.N., Soto M., Tavares C.A.P., Coelho E.A.F. Evaluation of parasitological and immunological parameters of Leishmania chagasi infection in BALB/c mice using different doses and routes of inoculation of parasites. Parasitol. Res. 2011, 107:1277-1285.
27. Rhodes S.G., Graham S.P. Is 'timing' important for cytokine polarization?. Trends Immunol. 2002, 23:246-249.
28. Sorimachi K., Akimoto K., Ikehara Y., Inafuku K., Okubo A., Yamazaki S. Secretion TNF-, IL-12 and nitric oxide by macrophages activated with Agaricus blazei Murill fractions in vitro. Cell Struct. Funct. 2001, 26:103-108.
29. Stäger S., Joshi T., Bankoti R. Immune evasive mechanisms contributing to persistent Leishmania donovani infection. Immunol. Res. 2010, 47:14-24.
30. Talcott J.A., Clark J.A., Lee I.P. Measuring perceived effects of drinking an extract of basidiomycetes Agaricus blazei Murill: a survey of Japanese consumers with cancer. BMC Complement Altern. Med. 2007, 29:7-32.
31. Tang N.Y., Yang J.S., Lin J.P., Hsia T.C., Fan M.J., Lin J.J., Weng S.W., Ma Y.S., Lu H.F., Shen J.J., Lin J.G., Chung J.G. Effects of Agaricus blazei Murill extract on immune responses in normal BALB/c mice. In Vivo (Athens, Greece) 2009, 23:761-766.
32. Tarascou I., Souquet J.M., Mazauric J.P., Carrillo S., Coq S., Canon F., Fulcrand H., Cheynier V. The hidden face of food phenolic composition. Arch. Biochem. Biophys. 2010, 501:16-22.
33. Valadares D.G., Duarte M.C., Oliveira J.S., Chávez-Fumagalli M.A., Martins V.T., Costa L.E., Leite J.P.V., Santoro M.M., Régis W.C.B., Tavares C.A.P., Coelho E.A.F. Leishmanicidal activity of the Agaricus blazei Murill in different Leishmania species. Parasitol. Int. 2011, 60:357-363.
34. Vieira L.Q., Goldschmidt M., Nashleanas M., Pfeffer K., Mak T., Scott P. Mice lacking the TNF receptor p55 fail to resolve lesions caused by infection with Leishmania major, but control parasite replication. J. Immunol. 1996, 157:827-835.
35. Wagner H., Bland S., Zgainski E.M. Plant Drug Analysis 1984, Springer-Verlag, Berlim, 320 p.
36. World Health Organization, 2009. The disease and its impact. http://who.int/emc/disease/leish/index.html.
37. Wu M.F., Hsu Y.M., Tang M.C., Chen H.C., Chung J.G., Lu H.F., Lin J.P., Tang N.Y., Yeh C., Yeh M.Y. Agaricus blazei Murill extract abrogates CCl4-induced liver injury in rats. In Vivo (Athens, Greece) 2011, 25:35-40.